401 related articles for article (PubMed ID: 30104711)
1. The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.
Sarwar M; Syed Khaja AS; Aleskandarany M; Karlsson R; Althobiti M; Ødum N; Mongan NP; Dizeyi N; Johnson H; Green AR; Ellis IO; Rakha EA; Persson JL
Oncogene; 2019 Jan; 38(3):375-389. PubMed ID: 30104711
[TBL] [Abstract][Full Text] [Related]
2. The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer.
Semenas J; Hedblom A; Miftakhova RR; Sarwar M; Larsson R; Shcherbina L; Johansson ME; Härkönen P; Sterner O; Persson JL
Proc Natl Acad Sci U S A; 2014 Sep; 111(35):E3689-98. PubMed ID: 25071204
[TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of ERα signaling and PIP5K1α/Akt pathways in castration-resistant prostate cancer.
Semenas J; Wang T; Sajid Syed Khaja A; Firoj Mahmud A; Simoulis A; Grundström T; Fällman M; Persson JL
Mol Oncol; 2021 Apr; 15(4):968-986. PubMed ID: 33275817
[TBL] [Abstract][Full Text] [Related]
4. The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer.
Larsson P; Syed Khaja AS; Semenas J; Wang T; Sarwar M; Dizeyi N; Simoulis A; Hedblom A; Wai SN; Ødum N; Persson JL
Int J Cancer; 2020 Mar; 146(6):1686-1699. PubMed ID: 31381135
[TBL] [Abstract][Full Text] [Related]
5. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
6. Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.
Sarwar M; Semenas J; Miftakhova R; Simoulis A; Robinson B; Gjörloff Wingren A; Mongan NP; Heery DM; Johnsson H; Abrahamsson PA; Dizeyi N; Luo J; Persson JL
Oncotarget; 2016 Sep; 7(39):63065-63081. PubMed ID: 27588408
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
8. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
10. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of casein kinase 1δ in breast cancer.
Rosenberg LH; Lafitte M; Quereda V; Grant W; Chen W; Bibian M; Noguchi Y; Fallahi M; Yang C; Chang JC; Roush WR; Cleveland JL; Duckett DR
Sci Transl Med; 2015 Dec; 7(318):318ra202. PubMed ID: 26676609
[TBL] [Abstract][Full Text] [Related]
12. RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo.
Cao XX; Xu JD; Xu JW; Liu XL; Cheng YY; Wang WJ; Li QQ; Chen Q; Xu ZD; Liu XP
Breast Cancer Res Treat; 2010 Sep; 123(2):375-86. PubMed ID: 19946739
[TBL] [Abstract][Full Text] [Related]
13. Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.
Maiti A; Takabe K; Hait NC
Cell Signal; 2017 Apr; 32():85-92. PubMed ID: 28108260
[TBL] [Abstract][Full Text] [Related]
14. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
15. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
16. Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway.
Adams LS; Phung S; Yee N; Seeram NP; Li L; Chen S
Cancer Res; 2010 May; 70(9):3594-605. PubMed ID: 20388778
[TBL] [Abstract][Full Text] [Related]
17. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
18. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
Liu CY; Huang TT; Chu PY; Huang CT; Lee CH; Wang WL; Lau KY; Tsai WC; Chao TI; Su JC; Chen MH; Shiau CW; Tseng LM; Chen KF
Exp Mol Med; 2017 Aug; 49(8):e366. PubMed ID: 28798401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]